{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T22:13:35Z","timestamp":1773094415884,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T00:00:00Z","timestamp":1561075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T00:00:00Z","timestamp":1561075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["115966"],"award-info":[{"award-number":["115966"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s40271-019-00367-w","type":"journal-article","created":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T05:59:21Z","timestamp":1561096761000},"page":"513-526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1982-4176","authenticated-orcid":false,"given":"Rosanne","family":"Janssens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selena","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eline","family":"van Overbeeke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Whichello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Harding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"K\u00fcbler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juhaeri","family":"Juhaeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin Sch\u00f6lin","family":"Bywall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"Comanescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Hueber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Englbrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikoletta","family":"Nikolenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Pravettoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Simoens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilde","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bennett","family":"Levitan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Cleemput","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"de Bekker-Grob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorien","family":"Veldwijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Huys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,21]]},"reference":[{"issue":"2","key":"367_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s40258-016-0299-1","volume":"15","author":"K Marsh","year":"2017","unstructured":"Marsh K, Caro JJ, Hamed A, Zaiser E. Amplifying each patient\u2019s voice: a systematic review of multi-criteria decision analyses involving patients. Appl Health Econ Health Policy. 2017;15(2):155\u201362.","journal-title":"Appl Health Econ Health Policy."},{"key":"367_CR2","unstructured":"Christiaens W, Kohn L, L\u00e9onard C, Denis A, Daue F, Cleemput I. Models for citizen and patient involvement in health care policy. Part I: exploration of their feasibility and acceptability. Health Services Research (HSR). Brussels: Belgian Health Care Knowledge Centre (KCE); 2012: report no.: KCE reports 195C, D\/2012\/10.273\/105."},{"key":"367_CR3","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health and Center for Biologics Evaluation and Research. Patient preference information: voluntary submission, review in premarket approval applications, humanitarian device exemption applications, and de novo requests, and inclusion in decision summaries and device labeling: guidance for industry, Food and Drug Administration staff, and other stakeholders. 2016. \n                    https:\/\/www.fda.gov\/media\/92593\/download\n                    \n                  ."},{"key":"367_CR4","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s10640-010-9450-x","volume":"49","author":"RT Carson","year":"2011","unstructured":"Carson RT, Louviere JJ. A Common nomenclature for stated preference elicitation approaches. Environ Resource Econ. 2011;49:539\u201359.","journal-title":"Environ Resource Econ"},{"issue":"4","key":"367_CR5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40290-014-0059-1","volume":"28","author":"MGM Weernink","year":"2014","unstructured":"Weernink MGM, Janus SIM, van Til JA, Raisch DW, van Manen JG, Ijzerman MJ. A systematic review to identify the use of preference elicitation methods in healthcare decision making. Pharm Med. 2014;28(4):175\u201385.","journal-title":"Pharm Med."},{"issue":"9","key":"367_CR6","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1111\/jdv.13749","volume":"30","author":"M Gutknecht","year":"2016","unstructured":"Gutknecht M, Schaarschmidt ML, Herrlein O, Augustin M. A systematic review on methods used to evaluate patient preferences in psoriasis treatments. J Eur Acad Dermatol Venereol. 2016;30(9):1454\u201364.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"1","key":"367_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40273-013-0118-6","volume":"32","author":"JA van Til","year":"2014","unstructured":"van Til JA, Ijzerman MJ. Why should regulators consider using patient preferences in benefit-risk assessment? Pharmacoeconomics. 2014;32(1):1\u20134.","journal-title":"Pharmacoeconomics."},{"issue":"6","key":"367_CR8","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jval.2016.04.006","volume":"19","author":"AC M\u00fchlbacher","year":"2016","unstructured":"M\u00fchlbacher AC, Juhnke C, Beyer AR, Garner S. Patient-focused benefit-risk analysis to inform regulatory decisions: the European Union perspective. Value Health. 2016;19(6):734\u201340.","journal-title":"Value Health."},{"issue":"6","key":"367_CR9","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1586\/14737167.2014.948852","volume":"14","author":"CD Dirksen","year":"2014","unstructured":"Dirksen CD. The use of research evidence on patient preferences in health care decision-making: issues, controversies and moving forward. Expert Rev Pharmacoecon Outcomes Res. 2014;14(6):785\u201394.","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"issue":"e1","key":"367_CR10","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1093\/jamia\/ocv149","volume":"23","author":"M Turley","year":"2016","unstructured":"Turley M, Wang S, Meng D, Kanter MH, Garrido T. An information model for automated assessment of concordance between advance care preferences and care delivered near the end of life. J Am Med Inform Assoc. 2016;23(e1):e118\u201324.","journal-title":"J Am Med Inform Assoc."},{"key":"367_CR11","unstructured":"European Medicines Agency, Stakeholders and Communication Division. The patient\u2019s voice in the evaluation of medicines. Report no. EMA\/607864\/2013. \n                    https:\/\/www.ema.europa.eu\/en\/documents\/report\/report-workshop-patients-voice-evaluation-medicines_en.pdf\n                    \n                  ."},{"key":"367_CR12","unstructured":"European Medicines Agency. Regulatory and methodological standards to improve benefit-risk evaluation of medicines 2014. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2014\/04\/WC500165803.pdf\n                    \n                  . Accessed 4 June 2019."},{"issue":"5","key":"367_CR13","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.clinthera.2014.04.011","volume":"36","author":"HL Peay","year":"2014","unstructured":"Peay HL, Hollin I, Fischer R, Bridges JF. A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy. Clin Ther. 2014;36(5):624\u201337.","journal-title":"Clin Ther."},{"issue":"5","key":"367_CR14","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1177\/2168479016662902","volume":"50","author":"MY Smith","year":"2016","unstructured":"Smith MY, Hammad TA, Metcalf M, Levitan B, Noel R, Wolka AM, et al. Patient engagement at a tipping point: the need for cultural change across patient, sponsor, and regulator stakeholders: insights from the DIA conference, \u201cPatient Engagement in Benefit Risk Assessment Throughout the Life Cycle of Medical Products\u201d. Ther Innov Regul Sci. 2016;50(5):546\u201353.","journal-title":"Ther Innov Regul Sci."},{"issue":"1","key":"367_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40271-014-0081-0","volume":"8","author":"JFP Bridges","year":"2014","unstructured":"Bridges JFP, Paly VF, Barker E, Kervitsky D. Identifying the benefits and risks of emerging treatments for idiopathic pulmonary fibrosis: a qualitative study. Patient. 2014;8(1):85\u201392.","journal-title":"Patient."},{"key":"367_CR16","doi-asserted-by":"publisher","first-page":"22761","DOI":"10.3402\/jmahp.v2.22761","volume":"2","author":"MO Egbrink","year":"2014","unstructured":"Egbrink MO, Ijzerman M. The value of quantitative patient preferences in regulatory benefit-risk assessment. J Mark Access Health Policy. 2014;2:22761.","journal-title":"J Mark Access Health Policy."},{"issue":"10","key":"367_CR17","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1007\/s00464-014-4044-2","volume":"29","author":"MP Ho","year":"2015","unstructured":"Ho MP, Gonzalez JM, Lerner HP, Neuland CY, Whang JM, McMurry-Heath M, et al. Incorporating patient-preference evidence into regulatory decision making. Surg Endosc. 2015;29(10):2984\u201393.","journal-title":"Surg Endosc."},{"issue":"6","key":"367_CR18","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.jval.2016.02.019","volume":"19","author":"M Ho","year":"2016","unstructured":"Ho M, Saha A, McCleary KK, Levitan B, Christopher S, Zandlo K, et al. A framework for incorporating patient preferences regarding benefits and risks into regulatory assessment of medical technologies. Value Health. 2016;19(6):746\u201350.","journal-title":"Value Health."},{"key":"367_CR19","unstructured":"Medical Device Innovation Consortium. Patient centered benefit-risk project report: a framework for incorporating information on patient preferences regarding benefit and risk into regulatory assessments of new medical technology. Arlington: Medical Device Innovation Consortium; 2015. \n                    http:\/\/mdic.org\/wp-content\/uploads\/2015\/05\/MDIC_PCBR_Framework_Web1.pdf\n                    \n                  ."},{"issue":"1","key":"367_CR20","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13023-016-0444-9","volume":"11","author":"T Morel","year":"2016","unstructured":"Morel T, Ayme S, Cassiman D, Simoens S, Morgan M, Vandebroek M. Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers. Orphanet J Rare Dis. 2016;11(1):70.","journal-title":"Orphanet J Rare Dis."},{"key":"367_CR21","unstructured":"Selig WKD. Key considerations for developing and integrating patient perspectives in drug development: examination of the duchenne case study. Biotechnology Innovation Organization and Parent Project Muscular Dystrophy; 2016. \n                    https:\/\/www.bio.org\/sites\/default\/files\/BIO_PPMD_Paper_2016.pdf\n                    \n                  ."},{"issue":"2","key":"367_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10198-016-0763-8","volume":"18","author":"AC M\u00fchlbacher","year":"2017","unstructured":"M\u00fchlbacher AC, Bridges JF, Bethge S, Dintsios CM, Schwalm A, Gerber-Grote A, et al. Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment. Eur J Health Econ. 2017;18(2):155\u201365.","journal-title":"Eur J Health Econ."},{"key":"367_CR23","unstructured":"Hughes D, Waddingham EAJ, Mt-Isa S, Goginsky A, Chan E, Downey G, et al. Recommendations for the methodology and visualisation techniques to be used in the assessment of benefit and risk of medicines. Innovative Medicines Initiative, Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium (PROTECT), Benefit-Risk Group; 2013. \n                    http:\/\/www.imi-protect.eu\/documents\/HughesetalRecommendationsforthemethodologyandvisualisationtechniquestobeusedintheassessmento.pdf\n                    \n                  ."},{"issue":"2","key":"367_CR24","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ijrobp.2014.09.044","volume":"91","author":"M Avila","year":"2015","unstructured":"Avila M, Becerra V, Guedea F, Suarez JF, Fernandez P, Macias V, et al. Estimating preferences for treatments in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2015;91(2):277\u201387.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"367_CR25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/1472-6963-14-287","volume":"14","author":"J Martin-Fernandez","year":"2014","unstructured":"Martin-Fernandez J, Polentinos-Castro E, del Cura-Gonzalez MI, Ariza-Cardiel G, Abraira V, Gil-LaCruz AI, et al. Willingness to pay for a quality-adjusted life year: an evaluation of attitudes towards risk and preferences. BMC Health Serv Res. 2014;14:287.","journal-title":"BMC Health Serv Res."},{"issue":"1","key":"367_CR26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1586\/14737167.2016.1115722","volume":"16","author":"DJ Mott","year":"2016","unstructured":"Mott DJ, Najafzadeh M. Whose preferences should be elicited for use in health-care decision-making? A case study using anticoagulant therapy. Expert Rev Pharmacoecon Outcomes Res. 2016;16(1):33\u20139.","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"issue":"4","key":"367_CR27","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1586\/14737167.2015.1038245","volume":"15","author":"AC M\u00fchlbacher","year":"2015","unstructured":"M\u00fchlbacher AC. Patient-centric HTA: different strokes for different folks. Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):591\u20137.","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"issue":"4","key":"367_CR28","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1017\/S0266462311000523","volume":"27","author":"M Danner","year":"2011","unstructured":"Danner M, Hummel JM, Volz F, Van Manen JG, Wiegard B, Dintsios CM, et al. Integrating patients\u2019 views into health technology assessment: analytic hierarchy process (AHP) as a method to elicit patient preferences. Int J Technol Assess Health Care. 2011;27(4):369\u201375.","journal-title":"Int J Technol Assess Health Care."},{"issue":"4","key":"367_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/BF03262495","volume":"5","author":"MJM Hummel","year":"2012","unstructured":"Hummel MJM, Volz F, Van Manen JG, Danner M, Dintsios CM, Ijzerman MJ, et al. Using the analytic hierarchy process to elicit patient preferences: prioritizing multiple outcome measures of antidepressant drug treatment. Patient. 2012;5(4):22\u201337.","journal-title":"Patient."},{"issue":"2","key":"367_CR30","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.drudis.2017.09.016","volume":"23","author":"SE Chaudhuri","year":"2018","unstructured":"Chaudhuri SE, Ho MP, Irony T, Sheldon M, Lo AW. Patient-centered clinical trials. Drug Discov Today. 2018;23(2):395\u2013401.","journal-title":"Drug Discov Today."},{"key":"367_CR31","unstructured":"European Medicines Agency. Values and preferences for treatment outcomes: the Macbeth approach. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Presentation\/2013\/10\/WC500153265.pdf\n                    \n                  . Accessed 4 June 2019."},{"key":"367_CR32","unstructured":"US FDA. PDUFA VI: PDUFA reauthorization performance goals and procedures fiscal years 2018 through 2022. 2016. \n                    https:\/\/www.fda.gov\/downloads\/ForIndustry\/UserFees\/PrescriptionDrugUserFee\/UCM511438.pdf\n                    \n                  . Accessed 4 June 2019."},{"key":"367_CR33","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration, Center for Biologics Evaluation and Research (CBER), editor. Patient-focused drug development: collecting comprehensive and representative input: guidance for industry, Food and Drug Administration staff, and other stakeholders: draft guidance; 2018. \n                    https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-collecting-comprehensive-and-representative-input\n                    \n                  ."},{"key":"367_CR34","unstructured":"U.S. Food and Drug Administration. FDA\u2019s external resources or information related to patients\u2019 experience. \n                    https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/external-resources-or-information-related-patients-experience\n                    \n                  . Accessed 14 Sept 2018."},{"issue":"3","key":"367_CR35","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40271-018-0305-9","volume":"11","author":"DJ Mott","year":"2018","unstructured":"Mott DJ. Incorporating quantitative patient preference data into healthcare decision making processes: is HTA falling behind? Patient. 2018;11(3):249\u201352.","journal-title":"Patient."},{"key":"367_CR36","unstructured":"Choice-based conjoint analysis: pilot project to identify, weight, and prioritize multiple attributes in the indication \u201chepatitis C\u201d. Institute for Quality and Efficiency in Health Care (IQWiG); 2014: report no. GA10-03."},{"key":"367_CR37","unstructured":"NICE. NICE provides first scientific advice on patient preference study design [updated 15 February 2019]. \n                    https:\/\/www.nice.org.uk\/news\/article\/nice-provides-first-scientific-advice-on-patient-preference-study-design\n                    \n                  . Accessed 4 June 2019."},{"issue":"5","key":"367_CR38","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/cpt.332","volume":"99","author":"D Postmus","year":"2016","unstructured":"Postmus D, Mavris M, Hillege HL, Salmonson T, Ryll B, Plate A, et al. Incorporating patient preferences into drug development and regulatory decision making: results from a quantitative pilot study with cancer patients, carers, and regulators. Clin Pharmacol Ther. 2016;99(5):548\u201354.","journal-title":"Clin Pharmacol Ther."},{"issue":"1","key":"367_CR39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40258-015-0203-4","volume":"14","author":"AC M\u00fchlbacher","year":"2016","unstructured":"M\u00fchlbacher AC, Kaczynski A. Making good decisions in healthcare with multi-criteria decision analysis: the use, current research and future development of MCDA. Appl Health Econ Health Policy. 2016;14(1):29\u201340.","journal-title":"Appl Health Econ Health Policy."},{"key":"367_CR40","volume-title":"Qualitative research practice: a guide for social science students and researchers","author":"J Ritchie","year":"2003","unstructured":"Ritchie J, Lewis J. Qualitative research practice: a guide for social science students and researchers. Thousand Oaks: SAGE Publications; 2003."},{"issue":"1","key":"367_CR41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1471-2288-13-117","volume":"13","author":"N Gale","year":"2013","unstructured":"Gale N, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol. 2013;13(1):117.","journal-title":"BMC Med Res Methodol."},{"key":"367_CR42","unstructured":"Lacey A, Luff D. Qualitative research analysis: the NIHR RDS for the East Midlands\/Yorkshire & the Humber; 2007. \n                    https:\/\/www.rds-yh.nihr.ac.uk\/wp-content\/uploads\/2013\/05\/9_Qualitative_Data_Analysis_Revision_2009.pdf\n                    \n                  ."},{"key":"367_CR43","unstructured":"US Food and Drug Administration. Webinar: final guidance on patient preference information. 2016. \n                    https:\/\/www.fda.gov\/MedicalDevices\/NewsEvents\/WorkshopsConferences\/ucm518783.htm\n                    \n                  . Accessed 4 June 2019."},{"key":"367_CR44","unstructured":"International Academy of Health Preference Research. \n                    https:\/\/iahpr.org\/\n                    \n                  . Accessed 14 Sept 2018."},{"issue":"4","key":"367_CR45","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s40271-017-0250-z","volume":"10","author":"FR Johnson","year":"2017","unstructured":"Johnson FR, Beusterien K, Ozdemir S, Wilson L. Giving patients a meaningful voice in United States regulatory decision making: the role for health preference research. Patient. 2017;10(4):523\u20136.","journal-title":"Patient."}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-019-00367-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40271-019-00367-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-019-00367-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T23:17:52Z","timestamp":1592608672000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40271-019-00367-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,21]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["367"],"URL":"https:\/\/doi.org\/10.1007\/s40271-019-00367-w","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,21]]},"assertion":[{"value":"21 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study is part of the PREFER project. PREFER is a 5-year project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant agreement no. 115966. This joint undertaking receives support from the European Union\u2019s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations. The funding source did not have a role in the study design, collection, analysis, and interpretation of the data, in the writing of the article, and in the decision to submit it for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"J\u00fcrgen K\u00fcbler\u2019s work was funded by CSL Behring. Bennett Levitan is an employee of Janssen Research and Development, LLC. He is a stockholder in Johnson & Johnson, Baxter International, Inc., Pharmaceutical Holders Trust, and Zimmer Holdings, Inc. He also owns stock in a variety of companies that at times include other pharmaceutical and healthcare-related companies. Richard Hermann is an employee and stockholder at AstraZeneca Pharmaceuticals, LP. Juhaeri Juhaeri is an employee of Sanofi and a holder of stock options and restricted shares of Sanofi. He also owns accounts in various investment companies that may include other biopharmaceutical and healthcare-related companies. Sarah Harding is an employee of Takeda International, UK Branch.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics approval was obtained in all countries where interviewees were recruited (registration number, country): Medical Ethics Committee of UZ KU Leuven\/Research (S59790, Belgium), Commission Nationale de l\u2019Informatique et des Libert\u00e9s (2036344, CNIL, France), Ethik-Kommission der Friedrich-Alexander Universit\u00e4t (92_17 B, Germany), Comitato Etico Instituto Europeo di Oncologia (R587\/17-IEO 609, Italy), Medisch Ethische Toetsings Commissie Erasmus Medical Centre (WT\/ss\/METC306661, the Netherlands), Comisia de Bioetica a Medicamentului si a Dispozitivelor Medicale [CNBMDM] (5 SNI, Romania), Regionala Etikpr\u00f6vningsn\u00e4mnden Uppsala (EPN] (2017\/001\/1, Sweden), Newcastle University Ethics Committee (11307\/2016, UK), and Western Institutional Review Board [WIRB] (1-1010535-1, USA).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All interviewees provided written informed consent to participate in the interview and for using the coded data of their interview for publication in scientific journals.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The data are not publicly available because they contain information that could compromise interviewees\u2019 privacy and consent.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}